JP2023549051A - Ｍａｇｌ阻害剤 - Google Patents
Ｍａｇｌ阻害剤 Download PDFInfo
- Publication number
- JP2023549051A JP2023549051A JP2023524567A JP2023524567A JP2023549051A JP 2023549051 A JP2023549051 A JP 2023549051A JP 2023524567 A JP2023524567 A JP 2023524567A JP 2023524567 A JP2023524567 A JP 2023524567A JP 2023549051 A JP2023549051 A JP 2023549051A
- Authority
- JP
- Japan
- Prior art keywords
- azaspiro
- octane
- hexafluoropropan
- carboxylate
- carbamoyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063113662P | 2020-11-13 | 2020-11-13 | |
| US63/113,662 | 2020-11-13 | ||
| PCT/EP2021/081522 WO2022101412A1 (en) | 2020-11-13 | 2021-11-12 | A magl inhibitor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023549051A true JP2023549051A (ja) | 2023-11-22 |
| JPWO2022101412A5 JPWO2022101412A5 (https=) | 2024-11-20 |
| JP2023549051A5 JP2023549051A5 (https=) | 2024-11-20 |
Family
ID=78709459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023524567A Pending JP2023549051A (ja) | 2020-11-13 | 2021-11-12 | Ｍａｇｌ阻害剤 |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US11434222B2 (https=) |
| EP (2) | EP4244208B1 (https=) |
| JP (1) | JP2023549051A (https=) |
| KR (1) | KR20230107225A (https=) |
| CN (2) | CN116547274B (https=) |
| AR (1) | AR124057A1 (https=) |
| AU (1) | AU2021379081A1 (https=) |
| CA (1) | CA3196119A1 (https=) |
| CL (1) | CL2023001339A1 (https=) |
| CO (1) | CO2023004649A2 (https=) |
| CR (1) | CR20230203A (https=) |
| DK (1) | DK4244208T3 (https=) |
| DO (1) | DOP2023000086A (https=) |
| ES (1) | ES3025484T3 (https=) |
| FI (1) | FI4244208T3 (https=) |
| GE (2) | GEP20257794B (https=) |
| HR (1) | HRP20250644T1 (https=) |
| HU (1) | HUE071543T2 (https=) |
| IL (1) | IL301818B1 (https=) |
| JO (1) | JOP20230091A1 (https=) |
| LT (1) | LT4244208T (https=) |
| MA (1) | MA62148B1 (https=) |
| MX (1) | MX2023005576A (https=) |
| PL (1) | PL4244208T3 (https=) |
| PT (1) | PT4244208T (https=) |
| RS (1) | RS66839B1 (https=) |
| SA (1) | SA523440403B1 (https=) |
| SI (1) | SI4244208T1 (https=) |
| TW (1) | TWI904281B (https=) |
| UA (1) | UA130186C2 (https=) |
| UY (1) | UY39516A (https=) |
| WO (1) | WO2022101412A1 (https=) |
| ZA (1) | ZA202304134B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190107A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| CA3242372A1 (en) | 2021-12-29 | 2023-07-06 | Psy Therapeutics, Inc. | Inhibiting monoacylglycerol lipase (magl) |
| KR20250005229A (ko) * | 2022-05-04 | 2025-01-09 | 하. 룬드벡 아크티에셀스카브 | 모노아실글리세롤 리파제 억제제로서 1,1,1,3,3,3-헥사플루오로프로판-2-일 (s)-1-(피리다진-3-일카르바모일)-6 아자스피로[2.5]옥탄-6-카르복실레이트의 결정질 형태 |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009506903A (ja) * | 2005-09-07 | 2009-02-19 | グレンクロス リミテッド | 水力式衝撃ユニット |
| JP2010527998A (ja) * | 2007-05-25 | 2010-08-19 | アストラゼネカ・アクチエボラーグ | スピロシクロプロピルピペリジン誘導体 |
| WO2012047703A2 (en) * | 2010-10-04 | 2012-04-12 | Schering Corporation | Cyclopropyl-spiro-piperidines useful as sodium channel blockers |
| JP2013527227A (ja) * | 2010-06-04 | 2013-06-27 | サノフイ | ヘキサフルオロイソプロピルカルバマート誘導体、この調製およびこの治療的用途 |
| JP2018533593A (ja) * | 2015-11-12 | 2018-11-15 | エーエフエーエスシーアイ，インコーポレイテッド | イオンチャネル阻害化合物、医薬製剤および使用 |
| JP2020532545A (ja) * | 2017-08-29 | 2020-11-12 | ルンドベック ラ ホーヤ リサーチ センター，インク． | スピロ環化合物並びにその作製及び使用方法 |
| JP2020532547A (ja) * | 2017-08-29 | 2020-11-12 | ルンドベック ラ ホーヤ リサーチ センター，インク． | スピロ環化合物並びにその作製及び使用方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110172230A1 (en) | 2006-08-23 | 2011-07-14 | Takahiro Ishii | Urea compound or salt thereof |
| US20100113465A1 (en) * | 2008-10-30 | 2010-05-06 | Pfizer Inc. | 7-azaspiro[3.5]nonane-7-carboxamide compounds |
| WO2010141817A1 (en) | 2009-06-05 | 2010-12-09 | Janssen Pharmaceutica Nv | Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase |
| PE20141702A1 (es) | 2012-01-06 | 2014-11-19 | Abide Therapeutics Inc | Compuestos de carbamato y preparacion y uso de los mismos |
| JP6404717B2 (ja) * | 2012-03-02 | 2018-10-17 | ジェネンテック， インコーポレイテッド | アミドスピロ環状アミド及びスルホンアミド誘導体 |
| KR102179599B1 (ko) | 2012-09-25 | 2020-11-19 | 에프. 호프만-라 로슈 아게 | 이환형 유도체 |
| JP6647592B2 (ja) | 2013-07-03 | 2020-02-14 | ルンドベック ラ ホーヤ リサーチ センター，インク． | ピロロピロールカルバメート、および関連する有機化合物、医薬組成物、ならびにその医学的使用 |
| MX2016013049A (es) | 2014-04-04 | 2017-04-27 | X-Rx Inc | Inhibidores de autotaxina espirociclicos sustituidos. |
| JP2018513119A (ja) | 2015-03-18 | 2018-05-24 | アビデ セラピューティクス，インク． | ピペラジンカルバメート、およびピペラジンカルバメートを製造ならびに使用する方法 |
| TN2017000544A1 (en) | 2015-07-31 | 2019-04-12 | Pfizer | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors |
| ES2804580T3 (es) | 2016-03-31 | 2021-02-08 | Takeda Pharmaceuticals Co | Compuesto heterocíclico |
| US10781211B2 (en) | 2016-05-12 | 2020-09-22 | Lundbeck La Jolla Research Center, Inc. | Spirocycle compounds and methods of making and using same |
| JOP20190107A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| JOP20190105A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| CN110198944A (zh) * | 2017-01-23 | 2019-09-03 | 辉瑞大药厂 | 作为单酰基甘油脂肪酶抑制剂的杂环螺环化合物 |
| KR20250005229A (ko) * | 2022-05-04 | 2025-01-09 | 하. 룬드벡 아크티에셀스카브 | 모노아실글리세롤 리파제 억제제로서 1,1,1,3,3,3-헥사플루오로프로판-2-일 (s)-1-(피리다진-3-일카르바모일)-6 아자스피로[2.5]옥탄-6-카르복실레이트의 결정질 형태 |
-
2021
- 2021-11-10 TW TW110141858A patent/TWI904281B/zh active
- 2021-11-11 UY UY0001039516A patent/UY39516A/es unknown
- 2021-11-11 US US17/524,632 patent/US11434222B2/en active Active
- 2021-11-12 SI SI202130311T patent/SI4244208T1/sl unknown
- 2021-11-12 MA MA62148A patent/MA62148B1/fr unknown
- 2021-11-12 GE GEAP202116246A patent/GEP20257794B/en unknown
- 2021-11-12 LT LTEPPCT/EP2021/081522T patent/LT4244208T/lt unknown
- 2021-11-12 MX MX2023005576A patent/MX2023005576A/es unknown
- 2021-11-12 WO PCT/EP2021/081522 patent/WO2022101412A1/en not_active Ceased
- 2021-11-12 DK DK21811018.7T patent/DK4244208T3/da active
- 2021-11-12 HU HUE21811018A patent/HUE071543T2/hu unknown
- 2021-11-12 AR ARP210103142A patent/AR124057A1/es unknown
- 2021-11-12 CN CN202180073621.0A patent/CN116547274B/zh active Active
- 2021-11-12 ES ES21811018T patent/ES3025484T3/es active Active
- 2021-11-12 CA CA3196119A patent/CA3196119A1/en active Pending
- 2021-11-12 IL IL301818A patent/IL301818B1/en unknown
- 2021-11-12 HR HRP20250644TT patent/HRP20250644T1/hr unknown
- 2021-11-12 CR CR20230203A patent/CR20230203A/es unknown
- 2021-11-12 GE GEAP202516246A patent/GEAP202516246A/en unknown
- 2021-11-12 UA UAA202301351A patent/UA130186C2/uk unknown
- 2021-11-12 KR KR1020237015365A patent/KR20230107225A/ko active Pending
- 2021-11-12 PL PL21811018.7T patent/PL4244208T3/pl unknown
- 2021-11-12 EP EP21811018.7A patent/EP4244208B1/en active Active
- 2021-11-12 FI FIEP21811018.7T patent/FI4244208T3/fi active
- 2021-11-12 AU AU2021379081A patent/AU2021379081A1/en active Pending
- 2021-11-12 RS RS20250496A patent/RS66839B1/sr unknown
- 2021-11-12 CN CN202512011225.8A patent/CN121824488A/zh active Pending
- 2021-11-12 US US18/252,611 patent/US20240018120A1/en active Pending
- 2021-11-12 PT PT218110187T patent/PT4244208T/pt unknown
- 2021-11-12 JP JP2023524567A patent/JP2023549051A/ja active Pending
- 2021-11-12 EP EP25166976.8A patent/EP4574150A3/en active Pending
-
2023
- 2023-04-04 ZA ZA2023/04134A patent/ZA202304134B/en unknown
- 2023-04-14 CO CONC2023/0004649A patent/CO2023004649A2/es unknown
- 2023-04-17 SA SA523440403A patent/SA523440403B1/ar unknown
- 2023-05-01 JO JOJO/P/2023/0091A patent/JOP20230091A1/ar unknown
- 2023-05-02 DO DO2023000086A patent/DOP2023000086A/es unknown
- 2023-05-09 CL CL2023001339A patent/CL2023001339A1/es unknown
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009506903A (ja) * | 2005-09-07 | 2009-02-19 | グレンクロス リミテッド | 水力式衝撃ユニット |
| JP2010527998A (ja) * | 2007-05-25 | 2010-08-19 | アストラゼネカ・アクチエボラーグ | スピロシクロプロピルピペリジン誘導体 |
| JP2013527227A (ja) * | 2010-06-04 | 2013-06-27 | サノフイ | ヘキサフルオロイソプロピルカルバマート誘導体、この調製およびこの治療的用途 |
| WO2012047703A2 (en) * | 2010-10-04 | 2012-04-12 | Schering Corporation | Cyclopropyl-spiro-piperidines useful as sodium channel blockers |
| JP2018533593A (ja) * | 2015-11-12 | 2018-11-15 | エーエフエーエスシーアイ，インコーポレイテッド | イオンチャネル阻害化合物、医薬製剤および使用 |
| JP2020532545A (ja) * | 2017-08-29 | 2020-11-12 | ルンドベック ラ ホーヤ リサーチ センター，インク． | スピロ環化合物並びにその作製及び使用方法 |
| JP2020532547A (ja) * | 2017-08-29 | 2020-11-12 | ルンドベック ラ ホーヤ リサーチ センター，インク． | スピロ環化合物並びにその作製及び使用方法 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2017353310B2 (en) | [1,2,4]triazolo[1,5-a]pyrimidine derivatives as PDE2 inhibitors | |
| CN116547274B (zh) | Magl抑制剂 | |
| KR20160144378A (ko) | 브루톤 티로신 키나제 억제제로서 작용하는 폴리플루오로화 화합물 | |
| CA2809557A1 (en) | Pyrazolopyridines as inhibitors of the kinase lrrk2 | |
| JP7253086B2 (ja) | アミノピリジン誘導体およびそれらの選択的ａｌｋ－２阻害剤としての使用 | |
| JP7130873B2 (ja) | バニン阻害剤としてのヘテロ芳香族化合物 | |
| KR20160055190A (ko) | 트립토판 하이드록실레이스 억제제로서 스파이로사이클릭 화합물 | |
| CN114786673A (zh) | Cdk抑制剂及其作为药物的用途 | |
| US11034696B2 (en) | Compounds for inhibiting LRRK2 kinase activity | |
| CA2820262A1 (en) | Bicyclic pyrazole compounds as allosteric modulators of mglur5 receptors | |
| EP3697781B1 (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
| TW202122382A (zh) | 乙內醯脲衍生物 | |
| CN108699080B (zh) | 6,7-二氢-5H-吡唑并[5,1-b][1,3]噁嗪-2-甲酰胺化合物 | |
| KR20250164854A (ko) | 치환된 인다졸 프로피온산 유도체 화합물 및 ampk 활성제로서의 이의 용도 | |
| CN119137114A (zh) | 作为单酰基甘油脂肪酶抑制剂的(s)-1-(哒嗪-3-基氨基甲酰基)-6-氮杂螺[2.5]辛烷-6-甲酸1,1,1,3,3,3-六氟丙-2-酯的结晶形式 | |
| HK40100721A (en) | A magl inhibitor | |
| HK40100721B (en) | A magl inhibitor | |
| EA048915B1 (ru) | Ингибитор magl | |
| CN116157388A (zh) | 一种碳环酰胺衍生物及其在医药上的应用 | |
| CN121399101A (zh) | Trek(twik相关k+通道)通道功能的抑制剂 | |
| TW202014191A (zh) | 具有選擇性ｂａｃｅ１抑制活性的四氫哌喃并衍生物 | |
| HK1262295A1 (en) | 6,7-dihydro-5h-pyrazolo[5，1-b][1,3]oxazine-2-carboxamide compounds | |
| HK1237335A1 (en) | Imidazopyridazine compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241111 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20241111 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20250925 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250930 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251217 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20260407 |